MIST
Milestone Pharmaceuticals Inc.
Overview
Milestone Pharmaceuticals designs and commercializes cardiovascular medicines. The company's FDA-approved product, CARDAMYST (etripamil) nasal spray, is a patient-administered treatment for acute episodes of paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals Inc is a Healthcare company operating in Biotechnology with a $163.1M market cap.
MIST missed consensus EPS by 1.0% in Q1 FY2026, reported May 12, 2026.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q1 FY20262026-05-12EPS$-0.20 vs $0.19-100.0%Rev$238.0K vs ——EODHD
- Q4 FY20252026-03-30EPS$-0.15 vs $-0.16+6.3%Rev$1.5M vs ——EODHD
- Q3 FY20252025-11-11EPS$-0.12 vs $-0.16+25.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-11EPS$-0.20 vs $-0.18-11.1%Rev$0 vs ——EODHD
- Q1 FY20252025-05-13EPS$-0.31 vs $-0.19-63.2%Rev$0 vs ——EODHD
- Q4 FY20242025-03-18EPS$-0.19 vs $-0.15-26.7%Rev$108.0K vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.14 vs $-0.18+22.2%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.14 vs $-0.20+30.0%Rev$0 vs ——EODHD
- Q1 FY20242024-05-12EPS$-0.21 vs $-0.27+22.2%Rev$-868.0K vs ——EODHD
- Q4 FY20232024-03-20EPS$-0.32 vs $-0.31-3.2%Rev$-868.0K vs ——EODHD
- Q3 FY20232023-11-12EPS$-0.35 vs $-0.39+10.3%Rev$0 vs ——EODHD
- Q2 FY20232023-08-09EPS$-0.37 vs $-0.39+5.1%Rev$0 vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.35 vs $-0.39+10.3%Rev$1.0M vs ——EODHD
- Q4 FY20222023-03-28EPS$-0.31 vs $-0.33+6.1%Rev$3.5M vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.34 vs $-0.41+17.1%Rev$1.5M vs ——EODHD
- Q2 FY20222022-08-09EPS$-0.39 vs $-0.37-5.4%Rev$0 vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.33 vs $-0.38+13.2%Rev$0 vs ——EODHD
- Q4 FY20212022-03-23EPS$-0.40 vs $-0.36-11.1%Rev$15.0M vs ——EODHD
- Q3 FY20212021-11-11EPS$-0.34 vs $-0.35+2.9%Rev$15.0M vs ——EODHD
- Q2 FY20212021-08-10EPS$0.02 vs $-0.35+100.0%Rev$15.0M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-12 | $-0.20 | $0.19 | -100.0% | $238.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-30 | $-0.15 | $-0.16 | +6.3% | $1.5M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.12 | $-0.16 | +25.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.20 | $-0.18 | -11.1% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-0.31 | $-0.19 | -63.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.19 | $-0.15 | -26.7% | $108.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.14 | $-0.18 | +22.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.14 | $-0.20 | +30.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.21 | $-0.27 | +22.2% | $-868.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.32 | $-0.31 | -3.2% | $-868.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.35 | $-0.39 | +10.3% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.37 | $-0.39 | +5.1% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.35 | $-0.39 | +10.3% | $1.0M | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $-0.31 | $-0.33 | +6.1% | $3.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.34 | $-0.41 | +17.1% | $1.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.39 | $-0.37 | -5.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.33 | $-0.38 | +13.2% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.40 | $-0.36 | -11.1% | $15.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.34 | $-0.35 | +2.9% | $15.0M | — | — | EODHD |
| Q2 FY2021 | 2021-08-10 | $0.02 | $-0.35 | +100.0% | $15.0M | — | — | EODHD |
Source: EODHD. MIST reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks MIST's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.04 | $0.83 | +25.1% | +2.5% | +1.6% |
| Q4 FY2026 | $1.26 | $1.04 | +20.8% | +3.9% | +2.1% |
| Q3 FY2026 | $0.96 | $0.80 | +19.4% | -5.0% | -3.0% |
| Q2 FY2026 | $1.34 | $1.09 | +22.8% | +5.1% | +2.3% |
| Q1 FY2025 | $1.18 | $0.92 | +28.8% | +3.8% | +1.5% |
| Q4 FY2025 | $1.15 | $0.96 | +19.6% | -4.7% | -5.8% |
| Q3 FY2025 | $1.30 | $1.06 | +22.6% | -0.7% | -2.8% |
| Q2 FY2025 | $1.17 | $0.98 | +19.0% | -2.8% | +0.1% |
| Q1 FY2024 | $1.23 | $1.05 | +17.2% | +3.4% | +0.8% |
| Q4 FY2024 | $1.24 | $0.97 | +27.8% | +1.2% | +0.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph OlivetoCEO1 yr 5 mo1 callCurrentSample
CEO since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
- Amit HasijaCFO1 yr 5 mo1 callCurrentSample
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
- Jeffrey Edward NelsonCOO1 yr 5 mono recorded callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
- David I SandovalGC & Chief Compliance Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- David BharuchaChief Medical Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Lorenz MullerChief Commercial Officer1 yr 5 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MIST.
$ curl https://api.spokenalpha.com/v1/companies/MISTFAQ
Frequently asked about MIST
Where can I find Milestone Pharmaceuticals Inc.'s (MIST) earnings call transcripts?
Spoken Alpha indexes MIST's earnings call transcripts at https://spokenalpha.com/companies/MIST. Each call links to attributed speakers and parsed analyst Q&A. Milestone Pharmaceuticals Inc.'s own investor relations page is at https://investors.milestonepharma.com/.
When was Milestone Pharmaceuticals Inc.'s most recent earnings call?
Milestone Pharmaceuticals Inc. (MIST) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
What sector is MIST in?
Milestone Pharmaceuticals Inc. (MIST) operates in the Healthcare sector (Biotechnology industry).